Cargando…
Exploring novel genetic and hematological predictors of response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer
Introduction: The standard treatment for locally advanced rectal cancer (LARC) is neoadjuvant chemoradiotherapy (nCRT). To select patients who would benefit the most from nCRT, there is a need for predictive biomarkers. The aim of this study was to evaluate the role of clinical, pathological, radiol...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10501402/ https://www.ncbi.nlm.nih.gov/pubmed/37719698 http://dx.doi.org/10.3389/fgene.2023.1245594 |
_version_ | 1785106109963436032 |
---|---|
author | Marinkovic, Mladen Stojanovic-Rundic, Suzana Stanojevic, Aleksandra Ostojic, Marija Gavrilovic, Dusica Jankovic, Radmila Maksimovic, Natasa Stroggilos, Rafael Zoidakis, Jerome Castellví-Bel, Sergi Fijneman, Remond J. A. Cavic, Milena |
author_facet | Marinkovic, Mladen Stojanovic-Rundic, Suzana Stanojevic, Aleksandra Ostojic, Marija Gavrilovic, Dusica Jankovic, Radmila Maksimovic, Natasa Stroggilos, Rafael Zoidakis, Jerome Castellví-Bel, Sergi Fijneman, Remond J. A. Cavic, Milena |
author_sort | Marinkovic, Mladen |
collection | PubMed |
description | Introduction: The standard treatment for locally advanced rectal cancer (LARC) is neoadjuvant chemoradiotherapy (nCRT). To select patients who would benefit the most from nCRT, there is a need for predictive biomarkers. The aim of this study was to evaluate the role of clinical, pathological, radiological, inflammation-related genetic, and hematological parameters in the prediction of post-nCRT response. Materials and methods: In silico analysis of published transcriptomics datasets was conducted to identify candidate genes, whose expression will be measured using quantitative Real Time PCR (qRT-PCR) in pretreatment formaline-fixed paraffin-embedded (FFPE) samples. In this study, 75 patients with LARC were prospectively included between June 2020—January 2022. Patients were assessed for tumor response in week 8 post-nCRT with pelvic MRI scan and rigid proctoscopy. For patients with a clinical complete response (cCR) and initially distant located tumor no immediate surgery was suggested (“watch and wait” approach). The response after surgery was assessed using histopathological tumor regression grading (TRG) categories from postoperative specimens by Mandard. Responders (R) were defined as patients with cCR without operative treatment, and those with TRG 1 and TRG 2 postoperative categories. Non-responders (NR) were patients classified as TRG 3-5. Results: Responders group comprised 35 patients (46.6%) and NR group 53.4% of patients. Analysis of published transcriptomics data identified genes that could predict response to treatment and their significance was assessed in our cohort by qRT-PCR. When comparison was made in the subgroup of patients who were operated (TRG1 vs. TRG4), the expression of IDO1 was significantly deregulated (p < 0.05). Among hematological parameters between R and NR a significant difference in the response was detected for neutrophil-to-monocyte ratio (NMR), initial basophil, eosinophil and monocyte counts (p < 0.01). According to MRI findings, non-responders more often presented with extramural vascular invasion (p < 0.05). Conclusion: Based on logistic regression model, factors associated with favorable response to nCRT were tumor morphology and hematological parameters which can be easily and routinely derived from initial laboratory results (NMR, eosinophil, basophil and monocyte counts) in a minimally invasive manner. Using various metrics, an aggregated score of the initial eosinophil, basophil, and monocyte counts demonstrated the best predictive performance. |
format | Online Article Text |
id | pubmed-10501402 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-105014022023-09-15 Exploring novel genetic and hematological predictors of response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer Marinkovic, Mladen Stojanovic-Rundic, Suzana Stanojevic, Aleksandra Ostojic, Marija Gavrilovic, Dusica Jankovic, Radmila Maksimovic, Natasa Stroggilos, Rafael Zoidakis, Jerome Castellví-Bel, Sergi Fijneman, Remond J. A. Cavic, Milena Front Genet Genetics Introduction: The standard treatment for locally advanced rectal cancer (LARC) is neoadjuvant chemoradiotherapy (nCRT). To select patients who would benefit the most from nCRT, there is a need for predictive biomarkers. The aim of this study was to evaluate the role of clinical, pathological, radiological, inflammation-related genetic, and hematological parameters in the prediction of post-nCRT response. Materials and methods: In silico analysis of published transcriptomics datasets was conducted to identify candidate genes, whose expression will be measured using quantitative Real Time PCR (qRT-PCR) in pretreatment formaline-fixed paraffin-embedded (FFPE) samples. In this study, 75 patients with LARC were prospectively included between June 2020—January 2022. Patients were assessed for tumor response in week 8 post-nCRT with pelvic MRI scan and rigid proctoscopy. For patients with a clinical complete response (cCR) and initially distant located tumor no immediate surgery was suggested (“watch and wait” approach). The response after surgery was assessed using histopathological tumor regression grading (TRG) categories from postoperative specimens by Mandard. Responders (R) were defined as patients with cCR without operative treatment, and those with TRG 1 and TRG 2 postoperative categories. Non-responders (NR) were patients classified as TRG 3-5. Results: Responders group comprised 35 patients (46.6%) and NR group 53.4% of patients. Analysis of published transcriptomics data identified genes that could predict response to treatment and their significance was assessed in our cohort by qRT-PCR. When comparison was made in the subgroup of patients who were operated (TRG1 vs. TRG4), the expression of IDO1 was significantly deregulated (p < 0.05). Among hematological parameters between R and NR a significant difference in the response was detected for neutrophil-to-monocyte ratio (NMR), initial basophil, eosinophil and monocyte counts (p < 0.01). According to MRI findings, non-responders more often presented with extramural vascular invasion (p < 0.05). Conclusion: Based on logistic regression model, factors associated with favorable response to nCRT were tumor morphology and hematological parameters which can be easily and routinely derived from initial laboratory results (NMR, eosinophil, basophil and monocyte counts) in a minimally invasive manner. Using various metrics, an aggregated score of the initial eosinophil, basophil, and monocyte counts demonstrated the best predictive performance. Frontiers Media S.A. 2023-08-31 /pmc/articles/PMC10501402/ /pubmed/37719698 http://dx.doi.org/10.3389/fgene.2023.1245594 Text en Copyright © 2023 Marinkovic, Stojanovic-Rundic, Stanojevic, Ostojic, Gavrilovic, Jankovic, Maksimovic, Stroggilos, Zoidakis, Castellví-Bel, Fijneman and Cavic. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Genetics Marinkovic, Mladen Stojanovic-Rundic, Suzana Stanojevic, Aleksandra Ostojic, Marija Gavrilovic, Dusica Jankovic, Radmila Maksimovic, Natasa Stroggilos, Rafael Zoidakis, Jerome Castellví-Bel, Sergi Fijneman, Remond J. A. Cavic, Milena Exploring novel genetic and hematological predictors of response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer |
title | Exploring novel genetic and hematological predictors of response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer |
title_full | Exploring novel genetic and hematological predictors of response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer |
title_fullStr | Exploring novel genetic and hematological predictors of response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer |
title_full_unstemmed | Exploring novel genetic and hematological predictors of response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer |
title_short | Exploring novel genetic and hematological predictors of response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer |
title_sort | exploring novel genetic and hematological predictors of response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer |
topic | Genetics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10501402/ https://www.ncbi.nlm.nih.gov/pubmed/37719698 http://dx.doi.org/10.3389/fgene.2023.1245594 |
work_keys_str_mv | AT marinkovicmladen exploringnovelgeneticandhematologicalpredictorsofresponsetoneoadjuvantchemoradiotherapyinlocallyadvancedrectalcancer AT stojanovicrundicsuzana exploringnovelgeneticandhematologicalpredictorsofresponsetoneoadjuvantchemoradiotherapyinlocallyadvancedrectalcancer AT stanojevicaleksandra exploringnovelgeneticandhematologicalpredictorsofresponsetoneoadjuvantchemoradiotherapyinlocallyadvancedrectalcancer AT ostojicmarija exploringnovelgeneticandhematologicalpredictorsofresponsetoneoadjuvantchemoradiotherapyinlocallyadvancedrectalcancer AT gavrilovicdusica exploringnovelgeneticandhematologicalpredictorsofresponsetoneoadjuvantchemoradiotherapyinlocallyadvancedrectalcancer AT jankovicradmila exploringnovelgeneticandhematologicalpredictorsofresponsetoneoadjuvantchemoradiotherapyinlocallyadvancedrectalcancer AT maksimovicnatasa exploringnovelgeneticandhematologicalpredictorsofresponsetoneoadjuvantchemoradiotherapyinlocallyadvancedrectalcancer AT stroggilosrafael exploringnovelgeneticandhematologicalpredictorsofresponsetoneoadjuvantchemoradiotherapyinlocallyadvancedrectalcancer AT zoidakisjerome exploringnovelgeneticandhematologicalpredictorsofresponsetoneoadjuvantchemoradiotherapyinlocallyadvancedrectalcancer AT castellvibelsergi exploringnovelgeneticandhematologicalpredictorsofresponsetoneoadjuvantchemoradiotherapyinlocallyadvancedrectalcancer AT fijnemanremondja exploringnovelgeneticandhematologicalpredictorsofresponsetoneoadjuvantchemoradiotherapyinlocallyadvancedrectalcancer AT cavicmilena exploringnovelgeneticandhematologicalpredictorsofresponsetoneoadjuvantchemoradiotherapyinlocallyadvancedrectalcancer |